Mustang Bio, Inc. (MBIO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Mustang Bio, Inc. on January 17, 2025, covering events occurring on January 14 and January 15, 2025. The Company, a Delaware corporation headquartered in Worcester, Massachusetts, is an emerging growth company listed on the Nasdaq Capital Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on a corporate action regarding the Company's capital structure.
Material Changes
The primary material change reported is the implementation of a 1-for-50 reverse stock split of the Company's common stock.
- Approval: Stockholders previously approved a reverse split ratio between 1-for-10 and 1-for-50 on July 10, 2024. The Board of Directors selected the 1-for-50 ratio on January 6, 2025.
- Effective Date: The reverse stock split became effective on January 15, 2025.
- Trading: Common stock began trading on a post-split basis on the Nasdaq Capital Market on January 16, 2025.
- Share Mechanics: Every 50 pre-split shares were combined into one post-split share. No fractional shares were issued; holders of fractional shares received cash payments in lieu thereof based on the closing price on the effective date.
- Identification: The post-split common stock has a new CUSIP number: 62818Q302. Par value and other terms remain unchanged.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the description of the amendment is qualified by reference to the filed Certificate of Amendment and the Definitive Information Statement on Schedule 14C.
Key Facts for Investor Verification
- Verify the new CUSIP number (62818Q302) for trading and record-keeping purposes.
- Confirm the number of shares held post-split (pre-split holdings divided by 50).
- Check for cash payments received in lieu of fractional shares if applicable.
- Review the Certificate of Amendment (Exhibit 3.1) and the Schedule 14C Information Statement for complete legal terms.